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PhosphorylationRecent data suggest that the adhesion docking protein NEDD9/HEF1/Cas-L is a critical regulator of adhesion-
dependent signalling pathways during mammary tumour development. Multiple phosphorylation modiﬁca-
tions of NEDD9 regulate interaction with downstream protein partners, thus the regulation of NEDD9
phospho-forms is an important point of control for NEDD9 function. As estradiol (E2) plays a central role in
the development and progression of breast cancer, we have investigated NEDD9 phospho-form regulation in
MCF-7 estrogen receptor (ER)-positive breast cancer cells in response to estrogen. We ﬁnd that levels of the
105-kDa NEDD9 phospho-form are signiﬁcantly increased after 3 days of estrogen exposure, and this is
suppressed by the anti-estrogen tamoxifen. Analysis of protein decay kinetics following treatment with the
protein synthesis inhibitor cycloheximide indicates that increased 105-kDa levels are due to a slower rate of
protein decay. Moreover, exogenous expression of NEDD9 failed to induce spreading in the presence of E2,
and this was reversed by tamoxifen treatment. Finally, we show that the 105-kDa NEDD9 phospho-form
appears to predominate in ER-positive versus ER-negative breast cancer cell lines. Taken together, our results
suggest that estradiol may suppress phospho-form-speciﬁc functions of NEDD9.+61 2 9845 3078.
.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
NEDD9/HEF1/Cas-L is a member of the Cas family of adhesion
dockingmolecules and has emerged as a key regulator ofmetastasis in
a number of different cancer types [1]. More recently, a speciﬁc role
for NEDD9 in breast cancer has emerged, particularly in the regulation
of oncogenic signalling pathways necessary for mammary tumour
progression [2]. Estrogen receptor (ER) status is a marker of breast
cancer prognosis, and estrogenmediated ER activity plays amajor role
in the progression of breast cancer. Mounting data suggest a role for
NEDD9 and the related Cas family protein p130Cas/BCAR1 in cellular
response to estrogen, including the progression to anti-estrogen
resistance [3,4]. The recently identiﬁed role for NEDD9 in breast
cancer progression means that it is now critical to establish the
molecular response of NEDD9 to estrogen.
The NEDD9 sequence encompasses multiple protein–protein
interaction domains that mediate interaction with downstream
signalling partners [5,6]. The demonstration that elevated NEDD9
expression stimulates cell spreading and migration in MCF-7 breast
cancer cells [7], along with other cell types [6], provided the initialsuggestion that NEDD9 may play a role in human breast cancer. This
has recently been conﬁrmed, with the report that genetic deletion of
NEDD9 signiﬁcantly delays primary tumour formation and reduces
cell spreading and metastatic progression in a mouse model of
mammary tumour development [2]. Deletion of NEDD9 caused
striking down-regulation of oncogenic signalling pathways in the
NEDD9−/− tumours that eventually formed, thus suggesting that
NEDD9 is a critical mediator of signalling pathways in breast cancer.
In human breast cancer, ER status is inversely correlated with
prognosis [8] and estrogen plays a multi-functional role in both
normal breast and breast cancer [9]. Importantly, it is now
appreciated that a portion of the ER associates with and regulates
cytoplasmic signalling molecules, thus stimulating intracellular
signalling cascades [10], including the Cas family protein p130Cas/
BCAR1 [11]. To date, the effect of estrogen on NEDD9 function is
unknown, and the recent discovery of the role for NEDD9 in
mammary tumour progression highlights the importance of investi-
gating NEDD9 regulation by estrogen.
NEDD9 is subject to extensive phosphorylation modiﬁcation,
evidenced by the 28 predicted consensus tyrosine phosphorylation
sites [12] and additional putative serine and threonine phosphoryla-
tion sites throughout the protein sequence. The large number of
phosphorylation modiﬁcations means that we currently only have
limited understanding of the role for individual phosphorylation sites.
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phospho-forms with different electrophoretic mobility that can easily
be monitored by Western blot analysis. 105-kDa NEDD9 is both
tyrosine and serine phosphorylated and undergoes further phosphor-
ylation modiﬁcations to produce a 115-kDa hyper-phosphorylated
protein that is serine, threonine, and tyrosine phosphorylated
[13–15]. 115-kDa NEDD9 is stimulated downstream of integrin-
mediated adhesion [14,16,17] and is lost following treatments that
disrupt the actin cytoskeleton [14,18]. The regulated interconversion
between the two NEDD9 phospho-forms suggests that this is an
important point of control for this molecule. NEDD9 is subject to tight
control of expression levels via post-translational protein degradation
mechanisms [17]. Importantly, interconversion between the NEDD9
phospho-forms regulates both the protein expression levels and
interaction with distinct binding partners [19,20].
The aim of the present study was therefore to investigate NEDD9
phospho-form regulation following estrogen stimulation of ER-
positive breast cancer cells. We establish that in estrogen treated
ER-positive cells, the 105-kDa NEDD9 phospho-form is preferentially
stabilized and NEDD9-mediated cell spreading is suppressed.
2. Materials and methods
2.1. Antibodies and reagents
Monoclonal antibodies to NEDD9 (clone 2G9) were either from
ImmuQuest (Cleveland, UK) or Cell Signalling Technology (MA, USA),
p130Cas from BD Biosciences (CA, USA), actin (C4) from Chemicon
International (CA, USA), and HSP70 from Sigma Aldrich (MO, USA).
HRP-conjugated anti-mouse antibodies were from Amersham Phar-
macia Biotech (NJ, USA) and Cy3-conjugated donkey anti-mouse from
Jackson Immunological Labs (PA, USA). Cycloheximide (CHX) was
purchased from Sigma Aldrich (MO, USA). Transfection reagent
Lipofectamine 2000 was obtained from Invitrogen Life Technologies
(CA, USA) and used according to the manufacturer's protocol.
2.2. Cell culture, protein extraction, and Western blotting
MCF-7 cells were maintained in Dulbecco's modiﬁed Eagle's
medium (DMEM) plus 10% Foetal Bovine Serum (FBS), MDA-MB-
134 and SKBR3 cells were maintained in Roswell Park Memorial
Institute (RPMI)-1640 supplemented with 10% FBS, glutamine
(6 mM), and insulin (10 μg/ml) and all cultures were maintained at
37 °C with 5% CO2. Hormone-free cell culture conditions and
supplementationwith 10nM17-β-estradiol and 1 μm4-OH tamoxifen
have been previously described [21]. Protein extracts from a panel of
ER-positive and ER-negative breast cancer lines were kindly provided
by Gillian Lerbach and Prof. Robert Sutherland from the Cancer
Research Program, Garvan Institute of Medical Research, Australia.
Cell growth and conditions of protein extraction have been previously
described [22]. Cell lysis of MCF-7 cells was achieved using PTY-lysis
buffer [16]. Protein concentrations were determined using a Pierce
BCA assay as per themanufacturer's instructions (Pierce, Rockford, IL),
and concentrations were then equalized. Proteins were separated in
6% SDS-polyacrylamide gels, followed by transfer to Immobilon
transfer membrane (0.45 μm, Millipore, MA, USA). Following incuba-
tion with indicated primary antibodies, membranes were incubated
with HRP-conjugated secondary antibodies as per manufacturer's
protocols. Blots were developed using Western Lighting Chemilumi-
nescence Reagent (PerkinElmer, MA, USA) and exposed to X-ray ﬁlm
(FujiFilm, Tokyo, Japan).
2.3. Protein analysis
Time course analysis of NEDD9 expression was performed by
extracting total cellular proteins at regular time points after additionof either estradiol or estradiol plus tamoxifen. All protein samples
were carefully equalized prior to Western blot analysis following
protein quantiﬁcation using a bicinchoninic acid Protein Assay Kit
(Pierce Biotechnology, IL, USA). Computer assisted densitometry and
analysis of protein expression was then achieved using ImageJ 1.34S
software (NIH, USA). Protein levels were expressed relative to the
zero time point and data plotted and analysed using GraphPad Prism
Software (GraphPad Software Inc, CA, USA). For analysis of protein
degradation, cycloheximide (CHX) (20 μg/ml) was added and pro-
teins extracted after 4-, 8-, 16-, and 24-h incubation in the presence of
CHX. For all experiments only the adherent cell population was
analyzed to speciﬁcally exclude any apoptotic cells that might have
arisen during the cycloheximide treatment. Following densitometry,
calculation of decay kinetics was performed using GraphPad Prism
Software (GraphPad Software Inc, CA, USA) as previously described
[23]. Data from quadruplicate repeats on separate days were used to
generate one-phase exponential decay curves in which the Span was
set at 100% and the plateau at 0%, to calculate the decay constant, k.
2.4. Transfection, microscopy, and image preparation
Expression plasmids encoding NEDD9 fused with GFP have been
previously described [16]. Following 7 days pre-treatment with
estradiol or estradiol plus tamoxifen cells were transfected with GFP
or GFP.NEDD9 expression constructs. For analysis of exogenous
protein turnover, 24 h post-transfection, half of the cultures were
treated with CHX (20 μg/ml) for 8 h, followed by protein extraction
and Western blot analysis. Cell ﬁxation and immunoﬂuorescence
were performed as described previously [18]. Immunostained cells
were mounted using FluorSave mounting reagent (CalBioChem/
Merck Sharp & Dohme, Australia). Images of ﬁxed cells were captured
using 60× (numerical aperture (NA), 1.35) and 40× (NA 0.5–1) oil
objectives and an ORCA ERG cooled CCD camera (Hamamatsu/SDR
Clinical Technology, Australia) mounted on an Olympus IX81 inverted
microscope using ﬂuorescence ﬁlters as follows: BP460-495/BP510-
550 (GFP) and BP530-550/BP575- 625 (CY3). Cell area measurements
were performed by outlining the periphery of GFP-positive cells on
bright-ﬁeld images. All round cells were excluded from this analysis
(Metamorph V6.3 software, Molecular Devices, Sunnyvale, CA). Final
micrograph images and gray level adjustments were prepared in
Adobe Photoshop.
3. Results
3.1. Estradiol stimulation increases 105-kDa NEDD9 levels
To investigate estrogen regulation of NEDD9 phospho-forms, we
compared expression of 105- and 115-kDa NEDD9 in ER-positive
MCF-7 cells cultured in hormone-depleted media supplemented with
17-β-estradiol (E2) alone, or in combination with the anti-estrogen
4-OH-tamoxifen (E2/TAM) to inhibit the effects of estradiol. This
analysis revealed accumulation of the 105-kDa form of NEDD9 in cells
treated with estradiol (Fig. 1A). We then conﬁrmed that the same
estradiol stimulation of 105-kDa NEDD9 accumulation is observed in a
second ER-positive line (MDA-MB-134) and further, no change is seen
in 105-kDa NEDD9 expression in an ER-negative cell line (SKBR3)
(Fig. 1A). Next, we quantiﬁed the levels of NEDD9 protein relative to
the starting concentration in the MCF-7 cells. This revealed a time-
dependent response in levels of NEDD9 phospho-forms. Critically,
105-kDa NEDD9 levels increased signiﬁcantly after 3 days culture in
E2 and this was sustained for up to 7 days (Fig. 1B). Importantly, this
effect was suppressed by E2/TAM (Fig. 1B). Conversely, 115-kDa
NEDD9 levels decreased for the ﬁrst few days of culture in either
media condition (Fig. 1C). By day 4, 115 kDa was restored to basal
levels in the E2 cultures, but there was signiﬁcant loss of 115-kDa
NEDD9 in E2/TAM cultures by day 7 (Fig. 1C). Collectively, these data
Fig. 1. Estradiol promotes 105-kDa NEDD9 accumulation. A. Protein extracts from ER-positive (ER+) MCF-7 and MDA-MB-134 cells and ER-negative (ER−) SKBR3 cells grown in
hormone-depleted media (control), media supplemented with estradiol (10 nM) alone (E2) and in combination with tamoxifen (1 μM) (E2/TAM) for 7 days. Western blots were
probed with monoclonal anti-NEDD9 antibodies. Histogram shows the ratio of 105- to 115-kD NEDD9, normalized to the matched control condition for each cell line. Data show the
average from three separate experiments. Error bars show the SEM. Statistical analysis was performed using one-way ANOVA with Tukey's Multiple Comparison test, *pb0.05,
NS=not signiﬁcant. B. Protein extracts from ER-positive MCF-7 cells grown in estradiol (E2) or estradiol plus tamoxifen (1 μM) (E2/TAM) supplemented media, for the indicated
number of days. Western blots were probed with monoclonal anti-NEDD9 antibodies and anti-tubulin antibodies to demonstrate equal protein loading. The predicted molecular
mass of NEDD9 is ~95 kDa and the faint band under the 105-kDa protein band likely represents unphosphorylated NEDD9. The ratio of 105- to 115-kDa NEDD9 across the time
course, normalized to the ratio at time zero, is shown in the histogram underneath. Data show the average from three separate experiments. Error bars show the SEM. C. 105-kDa
NEDD9 expression relative to the zero time point. D. 115-kDa NEDD9 expression relative to the zero time point. White circles show data for cells cultured in E2, and black circles
represent E2/TAM culture cells. All experiments were repeated in triplicate on separate days. Data points represent the average of three experiments (with the exception of the day 4
time point, which is from two data points only). The heavy signal of the tubulin blots reﬂects the quantity of total protein (N75 μg) required in order to visualize NEDD9; tubulin was
not used to normalize protein expression levels. Error bars show the SEM. Statistical analysis was performed using two-way ANOVA with Bonferroni post-tests, *pb0.05, **pb0.001.
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expression.
3.2. 105-kDa NEDD9 is stabilized in estradiol-treated cells
NEDD9 has a relatively short protein half-life, particularly when
compared with the highly stable related protein p130Cas/BCAR1 [17].
Thus we examined whether the increased levels of 105-kDa NEDD9 in
estradiol cultures might be due to reduced rates of protein
degradation. First, we determined the decay kinetics of total NEDD9
protein in control media, versus media supplemented with E2 or
E2/TAM. Following cycloheximide addition to arrest protein synthe-
sis, total NEDD9 protein degradation was greatest in cells cultured in
E2/TAM and slowest in cells cultured in E2 alone (Fig. 2A). Thisobservation was corroborated by quantiﬁcation of the rates of protein
decay (Fig. 2B), with signiﬁcantly slower NEDD9 protein turnover in
cells cultured in E2 and conversely signiﬁcantly faster turnover in
E2/TAM (Fig. 2C). Having established that estradiol stimulates
increased 105-kDa NEDD9 levels (Fig. 1), we therefore next calculated
105-kDa NEDD9 decay kinetics speciﬁcally. This analysis revealed that
105-kDa NEDD9 has a slower rate of decay in E2 versus either control
or E2/TAM media conditions (Fig. 2D), conﬁrmed by a signiﬁcantly
lower decay constant in E2 supplemented media (Fig. 2E). Thus it
appears that the rate of 105-kDa NEDD9 degradation is reduced in
cells cultured in E2.
As it has been previously reported using other cell systems that
p130Cas/BCAR1 protein is signiﬁcantly more stable than NEDD9
protein, we examined the decay kinetics of this protein under
Fig. 2. Accumulation of 105-kDa NEDD9 is due to increased protein stability. A. MCF-7
cells grown in hormone-depleted media conditions (control), supplemented with
estradiol (E2) and estradiol plus tamoxifen (E2/TAM). Cycloheximide (CHX) was added
for the indicated periods of time, followed by protein extraction, protein quantiﬁcation
and equalization, then analysis by Western blot with antibodies to NEDD9 and actin to
indicate equivalent protein loading. The heavy signal of the actin blots reﬂects the
quantity of total protein (N75 μg) required in order to visualize NEDD9; actin was not
used to normalize protein expression levels. B. Total NEDD9 protein levels under each
condition were measured by densitometry and expressed as a percentage of the protein
at time zero then regression analyses performed. C. Comparison of the decay constants
for total NEDD9 protein from cells grown in the indicated media conditions. D. Analysis
of 105-kDa NEDD9 performed as described for (B). Note that the trend lines for control
and+E2/TAM are superimposed and therefore appear as one line. E. Comparison of the
decay constants for 105-kDa NEDD9 under the indicated media conditions. All data are
from quadruplicate repeats on separate occasions, and error bars show the SEM. Values
were compared using one-way ANOVA with Tukey's Multiple Comparison test,
*pb0.05.
Fig. 3. p130Cas/BCAR1 is highly stable in all culture conditions. A. MCF-7 cells grown in
hormone-depleted media conditions (control), supplemented with estradiol (E2) and
estradiol plus tamoxifen (E2/TAM). B. Cycloheximide (CHX) was added for the
indicated periods of time, followed by protein extraction, protein quantiﬁcation, and
analysis by Western blot with antibodies to p130Cas and actin to indicate equivalent
protein loading. C. Total p130Cas protein levels under each condition weremeasured by
densitometry and expressed as a percentage of the protein at time zero then regression
analyses performed. All data are from quadruplicate repeats on separate occasions and
error bars show the SEM.
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treatment causes the accumulation of hyper-phosphorylated
p130Cas (Fig. 3A) as we have earlier reported [21]. Importantly, as
shown for other cell types, p130Cas/BCAR1 decay kinetics were
unaffected by the presence of either E2 or E2/TAM (Fig. 3A and B).
These data therefore conﬁrm speciﬁc stabilization of 105-kDa NEDD9
in estradiol.
3.3. Estradiol suppresses NEDD9-dependent cell spreading
Previous reports have demonstrated that exogenous NEDD9
expression induces a robust increase in cell spreading [7,24] and
conversely, tumour cells derived from a NEDD9 knockout mouse
mammary tumour model were signiﬁcantly less spread than their
wild-type counterparts [2]. Therefore, we next questioned the effects
of estradiol-mediated stabilization of 105-kDa NEDD9 on NEDD9-
mediated cell spreading. Importantly, cell spreading stimulated by
exogenous GFP.NEDD9 under control conditions (Fig. 4B) was
abrogated in cells pre-cultured in E2 prior to transfection (Fig. 4C),but restored in cells pre-cultured in E2/TAM (Fig. 4C). Notably,
exogenous NEDD9 localized to focal adhesions in both E2 and E2/TAM
conditions (Fig. 4A, arrows) and the exogenous protein exhibits
enhanced stability in the presence of E2 when compared with cells
grown in the presence of E2/TAM (Fig. 4D), similar to results seen
with the endogenous molecule (Fig. 2). Together, these data suggest
that estradiol suppresses NEDD9-mediated cell spreading.
3.4. 105-kDa NEDD9 is more highly expressed in ER-positive breast
cancer cell lines
Based on our data showing that 105-kDa NEDD9 accumulates in
response to estradiol, we next examined the expression of NEDD9
phospho-forms in a panel of ER-positive and ER-negative breast
cancer cell lines. All ER positive cell lines (8/8) had detectable levels of
NEDD9 protein (Fig. 5A). In contrast only 6/11 ER-negative cell lines
expressed detectable NEDD9 protein (Fig. 1A i, l, m, o, r, s). Notably,
we indeed observed a different pattern of 105- and 115-kDa phospho-
forms depending on ER status. 105-kDa NEDD9 predominated in the
ER-positive cells and conversely hyper-phosphorylated 115-kDa
NEDD9 predominated in the NEDD9-positive ER-negative cell lines
(Fig. 5A). Quantiﬁcation of the levels of 105-kDa NEDD9 relative to
total NEDD9 expression conﬁrmed that 105-kDa NEDD9 is expressed
at a signiﬁcantly higher level in ER-positive cells compared with ER
negative cells (Fig. 5B). Interestingly, the 6 ER-negative cell lines with
detectable NEDD9 protein (Fig. 5i,l,m,o,r,s) have signiﬁcantly higher
total NEDD9 expression than the ER-positive cell lines (Fig. 5C) due to
the high level of 115-kDa NEDD9 in the ER-negative cells. The ﬁnding
that 105-kDa NEDD9 predominates in ER-positive breast cancer cell
lines may therefore reﬂect the effects of estradiol on NEDD9 phospho-
forms in these cells.
4. Discussion
NEDD9 has been increasingly identiﬁed in screens for molecules of
signiﬁcance in cancer progression. Given recent reports that NEDD9
may play a role in oncogenic signalling in breast cancer [2], we
questioned whether NEDD9 may be part of estrogen stimulated
signalling networks. Indeed, we have demonstrated that the 105-kDa
Fig. 4. Estradiol suppresses NEDD9-dependent cell spreading. A. MCF-7 cells grown in hormone-depleted media conditions supplemented with estradiol (E2) and estradiol plus
tamoxifen (E2/TAM) were transfected with GFP vector control, or an expression plasmid encoding GFP-fused NEDD9. Arrows point to GFP.NEDD9 localized to focal adhesions. Scale bar
20 μm. B. Control MCF-7 cells transfectedwith GFP vector control, or an expression plasmid encoding GFP-fused NEDD9. Histogram shows the average area of cells expressing GFP-fused
NEDD9 compared to controls. Data are calculated from triplicate repeats on separate occasions and valueswere compared using a Students t-test, *pb0.05. C. Histogram shows the area of
GFP.NEDD9-positive cells (white bars) expressed as fold change relative to the area of GFP controls (black bars) in matching media conditions, as indicated. Data are calculated from
triplicate repeats on separate occasions. Values were compared using one-way ANOVA with Tukey's Multiple Comparison test, *pb0.05, NS=not signiﬁcant. D. Western blot analysis of
MCF-7 cells pre-cultured with E2 and E2/TAM as indicated, followed by transfection with a GFP.NEDD9 expression construct. Half of the samples were then treated with cycloheximide
(CHX) for 8 h. Blots were probedwith anti-NEDD9 antibodies to detect the NEDD9 GFP fusion proteins andwith antibodies to HSP70 as a loading control. Histogram shows densitometric
analysis of Western blots. Values are normalized to Hsp70 levels and expressed relative to the matched media conditions in the absence of CHX.
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with estrogen. Further, we show that estradiol suppresses NEDD9-
mediated cell spreading. Thus our data suggest that NEDD9 may have
a speciﬁc signalling function in the distinctive physiology of human
breast cancer.Fig. 5. NEDD9 expression and phosphorylation reﬂects ER status. A. Western blot
analysis of endogenous NEDD9 in 8 ER positive (a–h) and 11 ER negative (i–s) breast
cancer cell lines: a. BT-474, b. BT-483, c. MCF-7, d. MDA-MB-134, e. MDA-MB-175, f.
MDA-MB-361, g. T-47D, h. ZR-751, i.BT-20, j.BT-549, k.HBL-100, l.Hs578.T,
m.MDA-MB-157, n.MDA-MB-231, o.MDA-MB-330, p.MDA-MB-436, q.MDA-MB-453,
r.MDA-MB-468, s.SK-Br3. B. 105-kDa NEDD9 expression in NEDD9-positive cell lines
expressed as a percentage of total NEDD9. C. Quantiﬁcation of NEDD9 expression levels
in NEDD9-positive cell lines from panel A. Circles represent the density of NEDD9
expression for each cell line in arbitrary units (a.u.). Horizontal bars on the graphs
represent the mean. Statistical analysis performed using a Student's t-test, *pb0.05.Following exposure to either E2 or E2/TAM, total NEDD9 levels
initially decreased after which the levels were either restored or
further increased in the E2 treated cells. In agreement with our data,
previous reports have shown that NEDD9 mRNA levels decrease
following 24-h exposure to estrogen and anti-estrogens [25]. Thus
NEDD9 message appears to be initially down-regulated following
manipulation of estrogen signalling. Notably, TGF-β stimulation of
epithelial cells also causes an initial decrease in NEDD9 protein in
epithelial cells [15]. Similar to our results, initial TGF-β-mediated
down-regulation is followed by a compensatory increase in NEDD9
that continues to increasewith prolonged exposure to TGF-β [15]; this
effect appears to be cell type-dependent [14,15].
105-kDa NEDD9 is both tyrosine and serine phosphorylated
[13–15] and therefore is competent to interact with phosphoryla-
tion-dependent partner proteins. Reduced interconversion between
105- and 115-kDa NEDD9 in the estradiol treated cells may therefore
represent a mechanism to positively stimulate interaction with
105-kDa NEDD9-speciﬁc partners. In light of the role for NEDD9 in
cell cycle [19,26], cell survival [16,27] and migration/metastasis [1],
presumably normal functioning of this molecule requires tight
regulation of phosphorylation and expression levels. Although it is
well established that NEDD9 stimulates cell spreading, the relative
contributions of the 105- and 115-kDa NEDD9 phospho-forms to cell
spreading have not been reported. Recent studies have suggested
links between estrogen signalling and dynamic regulation of the actin
cytoskeleton [28,29]. We note that in preliminary data, we ﬁnd that
the activity of the actin-depolymerizing factor coﬁlin is not altered by
exogenous NEDD9 expression (data not shown), thus suggesting that
NEDD9 does notmediate cell spreading via a coﬁlin pathway. Our data
suggest that stabilization of 105-kDa NEDD9 may be inhibitory to
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phosphorylation event(s) that generates hyper-phosphorylated
115-kDa NEDD9 may be required for NEDD9-dependent cell spread-
ing. We have previously shown that phosphorylation status of the
related protein p130Cas also correlates with tamoxifen ER antagonist
effects [21]. However, in contrast to the data reported here for NEDD9,
p130Cas undergoes sustained hyper-phosphorylation in the presence
of tamoxifen and in the present study we demonstrate that p130Cas
protein turnover is unaffected by exposure to estrogen. Thus while
both proteins are regulated in response to estrogen, they display
differential regulation.
In line with our ﬁnding that estradiol stimulates the accumulation
of 105-kDa NEDD9, we ﬁnd that the 105-kDa phospho-form
predominates in ER-positive breast cancer cells that express NEDD9.
Interestingly, more than 50% of the ER-negative breast cancer cell
lineswere positive for NEDD9 and in these cells NEDD9was expressed
at high levels and exhibited a striking predominance of hyper-
phosphorylated 115-kDa NEDD9. Since ER-negative breast cancers
tend to be associated with more aggressive and treatment refractory
disease [30], our data suggest that increased levels of hyper-
phosphorylated NEDD9 may be associated with more aggressive
breast cancers. Due to the multi-functional role of NEDD9, we
speculate that estradiol suppression of NEDD9-mediated cell spread-
ing may reﬂect speciﬁc inhibition of NEDD9 function in cell spreading
and migration/metastasis. Potentially, loss of this control in the
ER-negative breast cancer cell lines may therefore de-regulate NEDD9
function in cell spreading and migration/metastasis. Of the ER-
positive cell lines, only the MDA-MB-175 cell line had a similar
pattern of NEDD9 expression and phosphorylation to the ER-negative
cell lines. This cell line has low ER expression (b10% expression when
compared with the ER cell lines examined) and is also progesterone
receptor-negative [31] and thus has a proﬁle more similar to
ER-negative cell lines.
Due to the complex nature of the phosphorylationmodiﬁcations of
NEDD9, little is currently known about the precise role for each
discrete phosphorylation site in mediating signalling through NEDD9.
It is clear, however, that phosphorylation is a major point of
regulatory control for this protein. Our ﬁndings that NEDD9
phosphorylation reﬂects ER status and that 105-kDa NEDD9 is
speciﬁcally stabilized in cells cultured in estrogen implicates NEDD9
function in the estrogen signalling networks that are critical to over
65% of all human breast cancers. The challenge now lies in
determining the signalling pathways activated downstream from
phosphorylation of speciﬁc residues in the sequence of NEDD9.
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